Brookside Capital Management Llc Decreased Clovis Oncology (Call) (CLVS) Stake By $26.11 Million; Smith A O (AOS) Sentiment Is 1.14

February 16, 2018 - By Marie Mckinney

A. O. Smith Corporation manufactures and markets residential and commercial gas, gas tankless, electric water heaters, and water treatment products in North America, China, Europe, and India. The company has market cap of $11.35 billion. The firm offers water heaters for residences, restaurants, hotels and motels, office buildings, laundries, car washes, and small businesses; commercial boilers for use in space heating applications for hospitals, schools, hotels, and other large commercial buildings; and expansion tanks, commercial solar water heating systems, swimming pool and spa heaters, and related products and parts. It has a 38.86 P/E ratio. It also provides heat pump and solar units, as well as combi boilers; and air purification products.

Brookside Capital Management Llc decreased Clovis Oncology Inc (Call) (NASDAQ:CLVS) stake by 98.58% reported in 2017Q4 SEC filing. Brookside Capital Management Llc sold 208,851 shares as Clovis Oncology Inc (Call) (NASDAQ:CLVS)’s stock declined 20.61%. The Brookside Capital Management Llc holds 3,000 shares with $375,000 value, down from 211,851 last quarter. Clovis Oncology Inc (Call) now has $2.68B valuation. The stock increased 0.20% or $0.11 during the last trading session, reaching $54.69. About 143,180 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since February 16, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.68 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

Investors sentiment decreased to 1.44 in 2017 Q3. Its down 0.37, from 1.81 in 2017Q2. It is negative, as 48 investors sold CLVS shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. Fifth Third Comml Bank holds 0% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 394 shares. 25,000 are held by Jefferies Gru Inc. Bain Public Equity Ltd Liability invested in 1.1% or 211,851 shares. Swiss National Bank & Trust holds 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 76,450 shares. Janney Montgomery Scott Ltd Llc owns 7,745 shares for 0.01% of their portfolio. Tocqueville Asset Mngmt L P has 83,135 shares for 0.08% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,819 shares. Goldman Sachs owns 336,486 shares or 0.01% of their US portfolio. Alpine Woods Cap Investors Ltd Liability holds 0.01% or 3,000 shares in its portfolio. Hanseatic Management Serv Inc accumulated 2,893 shares. Hbk Investments L P invested 0.02% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). 51,700 are held by Numeric Ltd Liability. Endurant Management Lp invested 1.42% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Prudential invested in 0.01% or 66,560 shares. Sectoral Asset Inc invested 2.67% in Clovis Oncology, Inc. (NASDAQ:CLVS).

In the 1980s, some Bain Consulting employees were looking for a way to provide investors with a direct profit stream utilizing the management skills learned at Bain. Thus Bain Capital was founded. Bain Capital was able to provide high returns by buying other companies, then using their Bain Consulting experience to improve the operations of the newly acquired firms. As the company expanded over time, Bain has become an organization for the management of large assets and has moved into other areas. Brookside Capital, a subsidiary of Bain Capital, uses fundamental analysis to manage its long/short public equities fund. It also makes use of industry and competitive insights, much as Bain Consulting did. Brookside Capital can be found investing in all economic sectors.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology has $134 highest and $15 lowest target. $71.11’s average target is 30.02% above currents $54.69 stock price. Clovis Oncology had 56 analyst reports since September 10, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, November 2 by RBC Capital Markets. The company was initiated on Tuesday, October 25 by Chardan Capital Markets. The company was maintained on Monday, January 25 by Mizuho. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, January 23 report. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Hold” rating given on Monday, July 31 by Oppenheimer. Piper Jaffray upgraded the shares of CLVS in report on Thursday, January 26 to “Overweight” rating. Leerink Swann maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Wednesday, November 15. Leerink Swann has “Buy” rating and $90.0 target. WallachBeth Capital downgraded Clovis Oncology, Inc. (NASDAQ:CLVS) on Tuesday, November 17 to “Hold” rating. The firm earned “Buy” rating on Friday, January 27 by Bank of America. On Friday, February 26 the stock rating was maintained by Stifel Nicolaus with “Buy”.

Since August 15, 2017, it had 0 insider buys, and 5 sales for $1.12 million activity. IVERS-READ GILLIAN C sold $210,150 worth of stock or 3,000 shares. SPICKSCHEN THORLEF had sold 4,500 shares worth $292,365 on Monday, January 8.

Since January 1, 0001, it had 0 insider purchases, and 2 sales for $2.51 million activity.

The stock increased 1.17% or $0.76 during the last trading session, reaching $65.99. About 261,622 shares traded. A. O. Smith Corporation (AOS) has risen 35.20% since February 16, 2017 and is uptrending. It has outperformed by 18.50% the S&P500.

Ecofin Ltd holds 9.01% of its portfolio in A. O. Smith Corporation for 632,100 shares. Water Asset Management Llc owns 286,602 shares or 8.52% of their US portfolio. Moreover, Marietta Investment Partners Llc has 5.68% invested in the company for 318,859 shares. The Texas-based Goodman Financial Corp has invested 3.57% in the stock. Agf Investments America Inc., a Ontario – Canada-based fund reported 154,987 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: